Editors
- Fatima Cardoso, Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Vesa Kataja, Central Finland Health Care District, Jyväskylä Central Hospital, Jyväskylä, Finland
- Vivianne Tjan-Heijnen, Maastricht University Medical Centre, Maastricht, Netherlands
Series editor: Michele Ghielmini, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
Contributors
Chapter 1 - Diagnosis and Staging of Breast Cancer and Multidisciplinary Team Working
- H Joensuu - Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
- M Leidenius - Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
Chapter 2 - Pathology (Including Normal Breast) and Disease Subtypes
- G Viale - Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan; University of Milan School of Medicine, Milan, Italy
- MG Mastropasqua - Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
Chapter 3 - Management of Carcinoma In Situ
- M-J Cardoso - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- C Vrieling - Department of Radiation Oncology, Clinique des Grangettes, Geneva, Switzerland
Chapter 4 - Breast Cancer Surgery
- P Dubsky - Department of Surgery, Medical University of Vienna, Vienna, Austria; Breast Centre, St. Anna, Lucerne, Switzerland
- W Haslik - Division of Plastic and Reconstructive Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria
Chapter 5 - Breast Cancer Radiotherapy
- I Kunkler - Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK
- V Kataja - Central Finland Health Care District, Jyväskylä Central Hospital, Jyväskylä, Finland
Chapter 6 - Adjuvant Systemic Therapies for Breast Cancer (Including Follow-up)
- N Turner -‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
- CD Hart - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
- L Biganzoli - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
- R Blum - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
- M Pestrin - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
- A Di Leo - ‘Sandro Pitigliani’ Medical Oncology Department, Prato Hospital, Istituto Toscano Tumori, Prato, Italy
Chapter 7 - Neoadjuvant Chemotherapy and Management of Locally Advanced Disease
- C Fontanella - German Breast Group, Neu-Isenburg, Germany; Department of Oncology, University Hospital of Udine, Udine, Italy
- G von Minckwitz - German Breast Group, Neu-Isenburg; University Women’s Hospital, Frankfurt; Senologic Oncology, Düsseldorf, Germany
Chapter 8 - Management of Metastatic Disease (Including Response Assessment)
- E Senkus - Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
- A Łacko - Department of Clinical Oncology, Wroclaw Medical University, Wrocław, Poland
Chapter 9 - Epidemiology of Breast Cancer
- M Pollán - Cancer and Environmental Epidemiology Unit, National Center of Epidemiology (Pab. 12), Instituto de Salud Carlos III, Madrid, Spain
Chapter 10 - Screening for Breast Cancer
- V Kataja - Central Finland Health Care District, Jyväskylä Central Hospital, Jyväskylä, Finland
Chapter 11 - Genetic Counselling and Testing
- O Pagani - Genetic Counselling Service of the Institute of Oncology of Southern Switzerland, Lugano, Switzerland
Chapter 12 - Prognostic and Predictive Factors
- F Penault-Llorca - Centre Régional de Lutte Contre le Cancer d’Auvergne, Clermont-Ferrand, France
Chapter 13 - New Targets and New Drugs for Breast Cancer
- G Curigliano - Division of Experimental Cancer Medicine, Istituto Europeo di Oncologia, Milan, Italy
Chapter 14 - Organ-specific Problems in Metastatic Breast Cancer
- T Cufer - University Clinic Golnik, Golnik, Slovenia
Chapter 15 - Metastatic Breast Cancer in Men
- F Cardoso - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- B Sousa - Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
Chapter 16 - Breast Cancer at the Extremes of Age
Part A: Breast Cancer in Young Women
- S Paluch-Shimon - Breast Oncology Unit, Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Israel
Part B: Breast Cancer in the Elderly
- H Wildiers - University Hospitals Leuven, Department of General Medical Oncology, Leuven, Belgium
Chapter 17 - Locally Recurrent Disease
- H Crezee - Department of Radiation Oncology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
- O Kaidar-Person - Department of Oncology, Radiation Oncology Unit, Rambam Health Care Campus, Haifa, Israel
- P Poortmans - Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands; Institut Curie, Paris, France
Declarations of interest
- L Biganzoli: No conflicts of interest.
- R Blum: No conflicts of interest.
- F Cardoso: No conflicts of interest.
- M-J Cardoso: No conflicts of interest.
- H Crezee: No conflicts of interest.
- T Cufer: No conflicts of interest.
- G Curigliano: Expert testimony for Pfizer, Novartis, Roche Genentech; Member of the Steering committee for randomised clinical trials of Cascadian, Roche Genentech, MacroGenics.
- A Di Leo: No conflicts of interest.
- P Dubsky: No conflicts of interest.
- C Fontanella: No conflicts of interest.
- CD Hart: No conflicts of interest.
- W Haslik: No conflicts of interest.
- H Joensuu: No conflicts of interest.
- O Kaidar-Person: No conflicts of interest.
- V Kataja: No conflicts of interest.
- I Kunkler: No conflicts of interest.
- A Łacko: Honoraria from AstraZeneca, Novartis, Roche; travel support from Roche.
- M Leidenius: No conflicts of interest.
- MG Mastropasqua: No conflicts of interest.
- O Pagani: No conflicts of interest.
- S Paluch-Shimon: No conflicts of interest.
- F Penault-Llorca: No conflicts of interest.
- M Pestrin: No conflicts of interest.
- M Pollán: No conflicts of interest.
- P Poortmans: No conflicts of interest.
- E Senkus: Honoraria from AstraZeneca, Celgene, Pfizer, Roche; travel support from Amgen, AstraZeneca, Pfizer, Roche.
- B Sousa: No conflicts of interest.
- N Turner: No conflicts of interest.
- G Viale: No conflicts of interest.
- G von Minckwitz: Research grants from GlaxoSmithKline, Novartis, Roche, Teva, Sanofi-Aventis.
- C Vrieling: No conflicts of interest.
- H Wildiers: No conflicts of interest.
